From the Blood Journals

From the Blood Journals

Research from the Blood family of journals: Blood and Blood Advances

Long-Term Study Highlights Limitations of Current TTP Diagnostic Methods

For the past two decades, ADAMTS13 activity has been the backbone of diagnosis for thrombotic thrombocytopenic purpura (TTP); however, a long-term registry study published...

Predicting Survival Outcomes for Children With Down Syndrome and AML or MDS

Children with Down syndrome (DS) have a higher risk of developing acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML) than those without DS....

Weighing the Risks and Benefits of Nivolumab in Patients With Hodgkin Lymphoma Undergoing AlloHCT

For patients with Hodgkin lymphoma (HL), allogeneic hematopoietic cell transplantation (alloHCT) can induce long-term disease control; however, relapse is common and rates of 3-year...

Pembrolizumab Induces Remission in Small Cohort of Patients With Natural Killer/T-Cell Lymphomas

For the 20 to 40 percent of patients with natural killer (NK)/T-cell lymphomas who do not respond to regimens such as SMILE (dexamethasone, methotrexate,...

Venetoclax Plus Obinutuzumab Effective in Older Adults With CLL and Comorbidities

Patients with chronic lymphocytic leukemia (CLL) are often older at the time of diagnosis (median age = 72 years), and typically receive treatment for...

Is Ibrutinib Tied to Ventricular Arrhythmias?

Previous studies have indicated that treatment with ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is associated with a 5 to 15 percent increase in...

Investigating Trends in Survival Outcomes Among the Oldest Patients with DLBCL

The probability of developing non-Hodgkin lymphoma (NHL) increases with age. Thus, as the U.S. population ages, a greater number of patients are at risk...

Can Pomalidomide Plus Dexamethasone “Rescue” Patients With Relapsed/ Refractory Amyloid Light-Chain Amyloidosis?

Patients with amyloid light-chain (AL) amyloidosis are often treated upfront with combinations of alkylating agents and bortezomib; when they don’t respond to this regimen...

Encouraging Trends in Six-Month Mortality in Amyloid Light-Chain Amyloidosis

With recent advances in diagnosis, treatment, and response assessment, clinicians have observed a significant decrease in six-month mortality (p<0.001) among patients with amyloid light-chain...

Can Podoplanin Explain the Connection Between Brain Tumors and Venous Thromboembolism?

Podoplanin, a sialomucin-like glycoprotein that can induce blood platelet activation, is frequently expressed by primary brain tumors. Its overexpression can contribute to a greater...

Current Issue

May 2017, Volume 3, Issue 6

This issue discusses the legacy of Agent Orange and hematologic malignancies, a debate over transplant in myelodysplastic syndromes, and more.